Netupitant - Helsinn
Alternative Names: R 1124; Ro 67-3189/000Latest Information Update: 26 Apr 2022
At a glance
- Originator Roche
- Developer Helsinn; Taiho Pharmaceutical
- Class Antiemetics; Pyridines; Small molecules
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chemotherapy-induced nausea and vomiting
- Discontinued Overactive bladder; Pruritus
Most Recent Events
- 26 Apr 2022 No development reported - Phase-II for Chemotherapy-induced nausea and vomiting (Combination therapy, In adolescents, In children, In infants, In neonates, Prevention) in USA, Russia, Serbia, Ukraine (PO)
- 30 Sep 2019 Helsinn Healthcare completes a phase II trial in Chemotherapy-induced nausea and vomiting (Combination therapy, In adolescents, In children, In infants, In neonates, Prevention) in Ukraine, Serbia, Russia and USA (PO) (NCT03204279)
- 20 Aug 2019 Netupitant is still in phase II clinical trials in Chemotherapy induced nausea and vomiting in USA (NCT03204279)